title: Preliminary evaluation of a predictive blood assay to identify patients at high risk of chemotherapy-induced nausea.
abstract: The aim of this study was to test a new blood-based assay for its ability to predict delayed chemotherapy-induced nausea.
  
  
  
  Blood drawn from consented patients prior to receiving their first platinum-based therapy was tested for glutathione recycling capacity and normalized to total red cell numbers. This number was used to predict nausea and then compared to patient reported outcomes using the Rotterdam Symptom Check List and medical records.
  
  
  
  We show that the pathways involved in the glutathione recycling are stable for at least 48 h and that the test was able to correctly classify the risk of nausea for 89.1 % of the patients. The overall incidence of nausea was 21.9 % while women had an incidence of 29.6 %.
  
  
  
  This might be the first objective test to predict delayed nausea for cancer patients receiving highly emetogenic chemotherapy. We believe that this assay could better guide clinicians in their efforts to provide optimal patient-oriented care.
authors.affiliation: Lankenau Institute for Medical Research, Lankenau Medical Center, Wynnewood, PA, 19096, USA.
authors.forename: Thomas
authors.initials: T
authors.lastname: Kutner
authors.affiliation: Lankenau Institute for Medical Research, Lankenau Medical Center, Wynnewood, PA, 19096, USA.
authors.forename: Emily
authors.initials: E
authors.lastname: Kunkel
authors.affiliation: Hematology/Oncology Fellowship Program, Lankenau Medical Center, Wynnewood, PA, 19096, USA.
authors.forename: Yue
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Lankenau Institute for Medical Research, Lankenau Medical Center, Wynnewood, PA, 19096, USA.
authors.forename: Kyle
authors.initials: K
authors.lastname: George
authors.affiliation: Lankenau Institute for Medical Research, Lankenau Medical Center, Wynnewood, PA, 19096, USA.|Department of Medical Oncology, Lankenau Medical Center, Wynnewood, PA, 19096, USA.
authors.forename: Erik L
authors.initials: EL
authors.lastname: Zeger
authors.affiliation: Lankenau Institute for Medical Research, Lankenau Medical Center, Wynnewood, PA, 19096, USA.|Department of Medical Oncology, Lankenau Medical Center, Wynnewood, PA, 19096, USA.
authors.forename: Zonera A
authors.initials: ZA
authors.lastname: Ali
authors.affiliation: Lankenau Institute for Medical Research, Lankenau Medical Center, Wynnewood, PA, 19096, USA.
authors.forename: George C
authors.initials: GC
authors.lastname: Prendergast
authors.affiliation: Lankenau Institute for Medical Research, Lankenau Medical Center, Wynnewood, PA, 19096, USA.|Department of Medical Oncology, Lankenau Medical Center, Wynnewood, PA, 19096, USA.
authors.forename: Paul B
authors.initials: PB
authors.lastname: Gilman
authors.affiliation: Lankenau Institute for Medical Research, Lankenau Medical Center, Wynnewood, PA, 19096, USA. wallon@limr.org.
authors.forename: U Margaretha
authors.initials: UM
authors.lastname: Wallon
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000932:Antiemetics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000097:blood* / Q000139:chemically induced; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy; D011446:Prospective Studies; D014839:Vomiting / Q000097:blood* / Q000139:chemically induced; D055815:Young Adult
chemical_list: D000932:Antiemetics
keywords: Blood test; CINV; Delayed nausea; Predictive test